Skip to content

Evaluation of a New Local Drug Delivery in the Nonsurgical Treatment of Periodontitis

Clinical, Biochemical and Microbiological Evaluation of a New Local Drug Delivery in the Nonsurgical Treatment of Periodontitis

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04862819
Enrollment
60
Registered
2021-04-28
Start date
2021-01-02
Completion date
2021-12-30
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis

Brief summary

The aim of the planned randomized clinical trial will be the clinical and microbiological evaluation of the new intracellular drug developed in cooperation with the Chair and Department of Drug Form Technology of the Medical University and the Department and Department of Pharmaceutical Microbiology and Parasitology of the Medical University in Wrocław.

Detailed description

Clinical trials will be conducted on 60 patients of the Department of Periodontology of the Medical University of Wrocław with 3rd or 4th degree generalized periodontitis, who will consent to participate in the research by signing the documentation approved by the Bioethics Committee of our University. The exclusion criteria will be: the presence of general diseases affecting the clinical condition of the periodontium, hypersensitivity to the drug used in the carrier system, lack of proper oral hygiene, active nicotinism and age over 65 years. The research will be carried out according to the scheme of parallel randomization and double-blinded trial in two groups of 30 people. All qualified patients will undergo an initial period of periodontal treatment and scaling / root planning. In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side, placebo with a change of side in every second patient. In the other group, the drug under evaluation or placebo will be used on one side, and the SRP treatment with alternation of sides on the other side for every second patient.

Interventions

DRUGnew local drug delivery

In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp

In the second group, on one side of the dental arch srp will be performed

Sponsors

Wroclaw Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* stage- 3rd degree generalized periodontitis * stage 4th degree generalized periodontitis

Exclusion criteria

* presence of general diseases affecting the clinical condition of the periodontium, * hypersensitivity to the drug used in the carrier system, * lack of proper oral hygiene * active nicotinism * age over 65 years

Design outcomes

Primary

MeasureTime frameDescription
changes in PD (pocket depth in millimetres )3 monthChange in depth of periodontal pockets measured from the bottom of the pocket to the edge of the gum in millimetres using periodontal probe
changes in CAL (clinical attachment level in millimetres )3 monthChange in clinical attachment level of periodontal pockets measured from the Cement-enamel junction to the bottom of the pocket in millimetres using periodontal probe
changes in microbiome (rt PCR test)3 monthchange in microbiological and biochemical parameters of pocket microbiome using PCR real time test 3 months after Local dryg delivery (LDD) application( taken from the gingival pocket with gingival fluid with a paper filter. There will be six bacterial strains and the bacterial total load assessed)

Countries

Poland

Contacts

Primary Contactjacek zborowski, phd
jacek.zborowski@umed.wroc.pl0048668446828

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026